Stock ZYDUSLIFE ZYDUS LIFESCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Market Closed - NSE India S.E.
Other stock markets
 07:42:32 2024-04-30 am EDT 		5-day change 1st Jan Change
953.6 INR -0.99% Intraday chart for Zydus Lifesciences Limited -0.64% +38.36%
Apr. 26 Weak March Quarter Earnings Weigh Down Indian Equities on Friday MT
Apr. 26 Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Weak March Quarter Earnings Weigh Down Indian Equities on Friday
MT
Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection
MT
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator
MT
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China
CI
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S
CI
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment
MT
Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US
MT
Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1
CI
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant
MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg
CI
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules
MT
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules
CI
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.
CI
Zydus Lifesciences Gets US FDA Final Nod for Chlorpromazine Hydrochloride Injection; Shares Jump 3%
MT
Zydus Receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials
CI
Zydus Receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial
CI
Zydus Lifesciences Launches Generic Cancer Drug Ibyra in India
MT
Zydus Lifesciences Limited Launches IBYRA, the Generic Version of Olaparib
CI
Zydus Lifesciences Gets US FDA's EIR for Ahmedabad, India Unit's Inspection
MT
Zydus Lifesciences Limited's Equity Buyback announced on February 9, 2024, has closed with 5,970,149 shares, representing 0.59% for INR 6,000 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZYDUSLIFE Stock
  4. News Zydus Lifesciences Limited
  5. Highlights